How much does rubicatin (rubitidine) cost? Drug unit price and economic evaluation at the time of purchase

Lurbinectedin (Lurbinectedin) is an anti-tumor drug used to treat recurrent small cell lung cancer. It has been launched in China. However, since it has just been launched, its specific price in domestic hospitals or pharmacies has not yet been clearly disclosed, and whether it is included in medical insurance has not yet been confirmed by authoritative documents. Therefore, patients may face problems of limited drug sources or opaque prices when purchasing domestically. It is recommended that patients in need go to a large tertiary hospital with oncology qualifications or contact the relevant drug service platform to learn about the latest sales and pricing.

In overseas markets, the price of Rubicatin is relatively high, especially the 4mg original drug sold in Hong Kong, which may be priced at 2 more than 10,000 yuan per box. Due to the impact of exchange rate fluctuations and regional pricing differences, the price may not be stable and may fluctuate at different points in time. Although it is expensive, because it is an original research version and the quality and safety of the drug are guaranteed, it is still the preferred purchasing channel for some patients. As a market with relatively concentrated medical resources and a relatively strict drug regulatory system, Hong Kong has become one of the important choices for many mainland patients to obtain Rubicatin.

In addition to the Hong Kong version, Ruby Card also has two main circulation versions overseas: the American version and the Singapore version. Among them, the US version of the original drug has the highest price, with a price of about more than 90,000 yuan per tube. It is mainly targeted at high-end people and insurance support systems in the European and American markets. The price of the version sold in the Singapore market is relatively moderate, about more than 30,000 yuan per unit. Both versions are original drugs with the same indications and usage standards. However, there is a significant price gap due to various factors such as the local medical system, tax rate, and distribution links. In the case of limited budget, some patients may prefer to choose the Singapore version or the Hong Kong version.

There are currently no generic drugs of Rubicatin on the market, and no alternative versions have yet been launched in common generic drug-producing countries such as India, Bangladesh, and Laos. This means that patients can only purchase higher-priced original drugs, which imposes a relatively heavy financial burden. Therefore, when purchasing drugs, patients should fully understand the price differences and drug sources between various versions, and choose a more appropriate drug purchasing channel based on their own economic conditions and treatment needs. At the same time, you can also pay attention to whether a generic version will be approved in the future to reduce long-term medication costs.

Reference materials:https://www.zepzelca.com/